William Blair Issues Pessimistic Forecast for OCUL Earnings

Key Points

• Ocular Therapeutix's Q3 2025 EPS estimate was lowered by analyst L. Hanbury-Brown of William Blair, now forecasting earnings of ($0.41) per share, down from a previous estimate of ($0.36).
• The company reported its latest quarterly earnings with actual EPS of ($0.39), which missed the analysts' consensus estimate by ($0.04).
• Ocular Therapeutix shares opened at $12.30 and have a market capitalization of $2.14 billion, with institutional investors owning 59.21% of the company's stock.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) - Equities research analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for Ocular Therapeutix in a research report issued to clients and investors on Tuesday, August 5th. William Blair analyst L. Hanbury-Brown now forecasts that the biopharmaceutical company will earn ($0.41) per share for the quarter, down from their prior forecast of ($0.36). The consensus estimate for Ocular Therapeutix's current full-year earnings is ($0.98) per share. William Blair also issued estimates for Ocular Therapeutix's Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.60) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.41) EPS and FY2026 earnings at ($1.59) EPS.

A number of other research firms have also issued reports on OCUL. Needham & Company LLC upped their price target on Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Finally, Scotiabank lowered their price objective on Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research report on Wednesday, August 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of "Buy" and a consensus target price of $17.20.

Ocular Therapeutix Price Performance

Shares of OCUL stock traded down $0.41 during trading hours on Friday, reaching $12.15. The company had a trading volume of 1,259,875 shares, compared to its average volume of 1,787,509. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.02 and a current ratio of 10.10. The stock has a fifty day moving average of $10.26 and a 200-day moving average of $8.41. The company has a market capitalization of $2.11 billion, a price-to-earnings ratio of -9.45 and a beta of 1.49. Ocular Therapeutix has a 12-month low of $5.78 and a 12-month high of $12.68.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The company had revenue of $13.46 million during the quarter, compared to analysts' expectations of $13.12 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. Ocular Therapeutix's revenue for the quarter was down 17.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.26) earnings per share.

Hedge Funds Weigh In On Ocular Therapeutix

Several large investors have recently bought and sold shares of the business. Sei Investments Co. grew its holdings in shares of Ocular Therapeutix by 19.3% during the fourth quarter. Sei Investments Co. now owns 27,742 shares of the biopharmaceutical company's stock worth $237,000 after purchasing an additional 4,496 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of Ocular Therapeutix during the fourth quarter worth about $149,000. Vanguard Group Inc. grew its holdings in shares of Ocular Therapeutix by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company's stock worth $72,453,000 after purchasing an additional 99,730 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Ocular Therapeutix by 123.6% during the fourth quarter. JPMorgan Chase & Co. now owns 189,295 shares of the biopharmaceutical company's stock worth $1,617,000 after purchasing an additional 104,650 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Ocular Therapeutix by 1.0% during the fourth quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company's stock worth $3,991,000 after buying an additional 4,488 shares during the last quarter. Hedge funds and other institutional investors own 59.21% of the company's stock.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,219 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the transaction, the insider directly owned 3,499,099 shares in the company, valued at $25,123,530.82. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 29,079 shares of company stock worth $208,739 in the last 90 days. 2.30% of the stock is owned by corporate insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.